T-DM1 Boosts Survival in HER2-Positive Breast Cancer

TOPLINE: Trastuzumab emtansine (T-DM1) demonstrates sustained improvement in invasive disease-free survival and reduced the risk for death in human epidermal growth factor receptor 2 (HER2)-positive breast cancer compared with trastuzumab. At 7 years, invasive disease-free survival and overall survival was 80.8% and 89.1%, respectively, with T-DM1 compared with 67.1% and 84.4%…